BIOTE CORP -A (BTMD) Fundamental Analysis & Valuation
NASDAQ:BTMD • US0906831039
Current stock price
1.79 USD
+0.2 (+12.58%)
Last:
This BTMD fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. BTMD Profitability Analysis
1.1 Basic Checks
- In the past year BTMD was profitable.
- In the past year BTMD had a positive cash flow from operations.
- BTMD had positive earnings in 4 of the past 5 years.
- Of the past 5 years BTMD 4 years had a positive operating cash flow.
1.2 Ratios
- With an excellent Return On Assets value of 25.13%, BTMD belongs to the best of the industry, outperforming 98.43% of the companies in the same industry.
- BTMD has a better Return On Invested Capital (44.85%) than 99.48% of its industry peers.
- BTMD had an Average Return On Invested Capital over the past 3 years of 32.37%. This is significantly above the industry average of 13.10%.
- The last Return On Invested Capital (44.85%) for BTMD is above the 3 year average (32.37%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 25.13% | ||
| ROE | N/A | ||
| ROIC | 44.85% |
ROA(3y)9.95%
ROA(5y)17.8%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)32.37%
ROIC(5y)N/A
1.3 Margins
- BTMD's Profit Margin of 14.07% is amongst the best of the industry. BTMD outperforms 87.43% of its industry peers.
- In the last couple of years the Profit Margin of BTMD has declined.
- BTMD's Operating Margin of 18.50% is amongst the best of the industry. BTMD outperforms 86.91% of its industry peers.
- BTMD's Operating Margin has declined in the last couple of years.
- The Gross Margin of BTMD (71.46%) is better than 78.53% of its industry peers.
- BTMD's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 18.5% | ||
| PM (TTM) | 14.07% | ||
| GM | 71.46% |
OM growth 3YN/A
OM growth 5Y-7.47%
PM growth 3YN/A
PM growth 5Y-10.89%
GM growth 3Y2.22%
GM growth 5Y3.08%
2. BTMD Health Analysis
2.1 Basic Checks
- With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), BTMD is creating value.
- BTMD has less shares outstanding than it did 1 year ago.
- The number of shares outstanding for BTMD has been increased compared to 5 years ago.
- BTMD has a better debt/assets ratio than last year.
2.2 Solvency
- BTMD has an Altman-Z score of 2.57. This is not the best score and indicates that BTMD is in the grey zone with still only limited risk for bankruptcy at the moment.
- BTMD has a Altman-Z score of 2.57. This is in the better half of the industry: BTMD outperforms 63.87% of its industry peers.
- The Debt to FCF ratio of BTMD is 4.43, which is a neutral value as it means it would take BTMD, 4.43 years of fcf income to pay off all of its debts.
- The Debt to FCF ratio of BTMD (4.43) is better than 84.82% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 4.43 | ||
| Altman-Z | 2.57 |
ROIC/WACC5.7
WACC7.87%
2.3 Liquidity
- A Current Ratio of 1.22 indicates that BTMD should not have too much problems paying its short term obligations.
- The Current ratio of BTMD (1.22) is worse than 81.15% of its industry peers.
- A Quick Ratio of 0.79 indicates that BTMD may have some problems paying its short term obligations.
- The Quick ratio of BTMD (0.79) is worse than 85.34% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.22 | ||
| Quick Ratio | 0.79 |
3. BTMD Growth Analysis
3.1 Past
- The Earnings Per Share has grown by an impressive 277.27% over the past year.
- Measured over the past years, BTMD shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -26.76% on average per year.
- The Revenue for BTMD has decreased by -21.22% in the past year. This is quite bad
- BTMD shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 10.51% yearly.
EPS 1Y (TTM)277.27%
EPS 3YN/A
EPS 5Y-26.76%
EPS Q2Q%-40%
Revenue 1Y (TTM)-21.22%
Revenue growth 3Y5.22%
Revenue growth 5Y10.51%
Sales Q2Q%-6.87%
3.2 Future
- BTMD is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 9.65% yearly.
- BTMD is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 8.86% yearly.
EPS Next Y-63.75%
EPS Next 2Y-33.79%
EPS Next 3Y-8.66%
EPS Next 5Y9.65%
Revenue Next Year0.32%
Revenue Next 2Y3.4%
Revenue Next 3Y4.7%
Revenue Next 5Y8.86%
3.3 Evolution
- The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
- The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
4. BTMD Valuation Analysis
4.1 Price/Earnings Ratio
- With a Price/Earnings ratio of 2.16, the valuation of BTMD can be described as very cheap.
- BTMD's Price/Earnings ratio is rather cheap when compared to the industry. BTMD is cheaper than 98.95% of the companies in the same industry.
- BTMD is valuated cheaply when we compare the Price/Earnings ratio to 27.18, which is the current average of the S&P500 Index.
- A Price/Forward Earnings ratio of 5.95 indicates a rather cheap valuation of BTMD.
- Compared to the rest of the industry, the Price/Forward Earnings ratio of BTMD indicates a rather cheap valuation: BTMD is cheaper than 95.29% of the companies listed in the same industry.
- Compared to an average S&P500 Price/Forward Earnings ratio of 37.96, BTMD is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 2.16 | ||
| Fwd PE | 5.95 |
4.2 Price Multiples
- Based on the Enterprise Value to EBITDA ratio, BTMD is valued cheaply inside the industry as 97.38% of the companies are valued more expensively.
- Based on the Price/Free Cash Flow ratio, BTMD is valued cheaper than 98.95% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 2.48 | ||
| EV/EBITDA | 4.18 |
4.3 Compensation for Growth
- The decent profitability rating of BTMD may justify a higher PE ratio.
- A cheap valuation may be justified as BTMD's earnings are expected to decrease with -8.66% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-33.79%
EPS Next 3Y-8.66%
5. BTMD Dividend Analysis
5.1 Amount
- No dividends for BTMD!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
BTMD Fundamentals: All Metrics, Ratios and Statistics
NASDAQ:BTMD (4/13/2026, 8:12:01 PM)
1.79
+0.2 (+12.58%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)03-11 2026-03-11/amc
Earnings (Next)05-05 2026-05-05
Inst Owners63.53%
Inst Owner Change0.07%
Ins Owners9.77%
Ins Owner Change0%
Market Cap70.35M
Revenue(TTM)192.22M
Net Income(TTM)27.05M
Analysts81.82
Price Target3.24 (81.01%)
Short Float %5.7%
Short Ratio7.53
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)189.9%
Min EPS beat(2)17.65%
Max EPS beat(2)362.15%
EPS beat(4)4
Avg EPS beat(4)254.13%
Min EPS beat(4)17.65%
Max EPS beat(4)458.07%
EPS beat(8)5
Avg EPS beat(8)90.98%
EPS beat(12)7
Avg EPS beat(12)15.74%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-1.53%
Min Revenue beat(2)-1.55%
Max Revenue beat(2)-1.5%
Revenue beat(4)1
Avg Revenue beat(4)-1.18%
Min Revenue beat(4)-3.31%
Max Revenue beat(4)1.66%
Revenue beat(8)2
Avg Revenue beat(8)-1.59%
Revenue beat(12)4
Avg Revenue beat(12)-1.42%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-34.47%
PT rev (3m)-37.68%
EPS NQ rev (1m)-13.64%
EPS NQ rev (3m)-13.64%
EPS NY rev (1m)18%
EPS NY rev (3m)14.93%
Revenue NQ rev (1m)-2.92%
Revenue NQ rev (3m)-3.12%
Revenue NY rev (1m)-2%
Revenue NY rev (3m)-2.41%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 2.16 | ||
| Fwd PE | 5.95 | ||
| P/S | 0.37 | ||
| P/FCF | 2.48 | ||
| P/OCF | 2 | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | 4.18 |
EPS(TTM)0.83
EY46.37%
EPS(NY)0.3
Fwd EY16.81%
FCF(TTM)0.72
FCFY40.27%
OCF(TTM)0.9
OCFY50.03%
SpS4.89
BVpS-1.49
TBVpS-1.86
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 25.13% | ||
| ROE | N/A | ||
| ROCE | 56.77% | ||
| ROIC | 44.85% | ||
| ROICexc | 72.95% | ||
| ROICexgc | 117.64% | ||
| OM | 18.5% | ||
| PM (TTM) | 14.07% | ||
| GM | 71.46% | ||
| FCFM | 14.74% |
ROA(3y)9.95%
ROA(5y)17.8%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)32.37%
ROIC(5y)N/A
ROICexc(3y)67.85%
ROICexc(5y)N/A
ROICexgc(3y)109.57%
ROICexgc(5y)N/A
ROCE(3y)40.97%
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5Y-44.74%
ROICexc growth 3YN/A
ROICexc growth 5Y-35.99%
OM growth 3YN/A
OM growth 5Y-7.47%
PM growth 3YN/A
PM growth 5Y-10.89%
GM growth 3Y2.22%
GM growth 5Y3.08%
F-Score7
Asset Turnover1.79
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 4.43 | ||
| Debt/EBITDA | 2.57 | ||
| Cap/Depr | 187.03% | ||
| Cap/Sales | 3.57% | ||
| Interest Coverage | 4.51 | ||
| Cash Conversion | 89.73% | ||
| Profit Quality | 104.75% | ||
| Current Ratio | 1.22 | ||
| Quick Ratio | 0.79 | ||
| Altman-Z | 2.57 |
F-Score7
WACC7.87%
ROIC/WACC5.7
Cap/Depr(3y)157.42%
Cap/Depr(5y)165.61%
Cap/Sales(3y)2.85%
Cap/Sales(5y)2.48%
Profit Quality(3y)682.14%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)277.27%
EPS 3YN/A
EPS 5Y-26.76%
EPS Q2Q%-40%
EPS Next Y-63.75%
EPS Next 2Y-33.79%
EPS Next 3Y-8.66%
EPS Next 5Y9.65%
Revenue 1Y (TTM)-21.22%
Revenue growth 3Y5.22%
Revenue growth 5Y10.51%
Sales Q2Q%-6.87%
Revenue Next Year0.32%
Revenue Next 2Y3.4%
Revenue Next 3Y4.7%
Revenue Next 5Y8.86%
EBIT growth 1Y-15.43%
EBIT growth 3YN/A
EBIT growth 5Y2.26%
EBIT Next Year14.18%
EBIT Next 3Y14.95%
EBIT Next 5Y17.45%
FCF growth 1Y-26.01%
FCF growth 3YN/A
FCF growth 5Y2.5%
OCF growth 1Y-22.21%
OCF growth 3YN/A
OCF growth 5Y5.89%
BIOTE CORP -A / BTMD Fundamental Analysis FAQ
Can you provide the ChartMill fundamental rating for BIOTE CORP -A?
ChartMill assigns a fundamental rating of 6 / 10 to BTMD.
Can you provide the valuation status for BIOTE CORP -A?
ChartMill assigns a valuation rating of 8 / 10 to BIOTE CORP -A (BTMD). This can be considered as Undervalued.
What is the profitability of BTMD stock?
BIOTE CORP -A (BTMD) has a profitability rating of 7 / 10.
What is the financial health of BIOTE CORP -A (BTMD) stock?
The financial health rating of BIOTE CORP -A (BTMD) is 5 / 10.
What is the earnings growth outlook for BIOTE CORP -A?
The Earnings per Share (EPS) of BIOTE CORP -A (BTMD) is expected to decline by -63.75% in the next year.